Currently in the development phase, Cellares’ automated platform will be suitable for producing CAR-T, hematopoietic stem cells (HSC), T-cell receptor (TCR), natural killer (NK), TIL (Tumor infiltrating lymphocytes), T-reg, and γδ T cells . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge